Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jun Wang, Lu Yang, Feng-Ting Dao, Ya-Zhe Wang, Yan Chang, Nan Xu, Wen-Min Chen, Qian Jiang, Hao Jiang, Yan-Rong Liu & Ya-Zhen Qin. (2022) Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia. Leukemia & Lymphoma 63:1, pages 152-161.
Read now
Read now
Lingli Chen, Jianfeng Hong, Renjing Hu, Xiaomei Yu, Xindong Chen, Shaoxiong Zheng, Yuan Qin, Xiumei Zhou, Yigang Wang, Liping Zheng, Hongming Fang, Pengfei Liu & Biao Huang. (2021) Clinical Value of Combined Detection of Serum sTim-3 and Pepsinogen for Gastric Cancer Diagnosis. Cancer Management and Research 13, pages 7759-7769.
Read now
Read now
Amer M Zeidan, Rami S Komrokji & Andrew M Brunner. (2021) TIM-3 pathway dysregulation and targeting in cancer. Expert Review of Anticancer Therapy 21:5, pages 523-534.
Read now
Read now
Zhe Ge, Shan Wu, Zhe Zhang & Shuzhe Ding. (2020) Mechanism of tumor cells escaping from immune surveillance of NK cells. Immunopharmacology and Immunotoxicology 42:3, pages 187-198.
Read now
Read now
Yayi He, Jie Cao, Chao Zhao, Xuefei Li, Caicun Zhou & Fred R Hirsch. (2018) TIM-3, a promising target for cancer immunotherapy. OncoTargets and Therapy 11, pages 7005-7009.
Read now
Read now
Zhenxin Wang, Ni Yin, Zixiang Zhang, Yi Zhang, Guangbo Zhang & Weichang Chen. (2017) Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression. Immunological Investigations 46:2, pages 134-148.
Read now
Read now
Articles from other publishers (56)
Hao Jia, Hongmei Yang, Huaxing Xiong & Kathy Qian Luo. (2023) NK cell exhaustion in the tumor microenvironment. Frontiers in Immunology 14.
Crossref
Crossref
Natalia Sauer, Natalia Janicka, Wojciech Szlasa, Bartłomiej Skinderowicz, Katarzyna Kołodzińska, Wioletta Dwernicka, Małgorzata Oślizło, Julita Kulbacka, Vitalij Novickij & Katarzyna Karłowicz-Bodalska. (2023) TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunology, Immunotherapy.
Crossref
Crossref
Takanori Kitamura. (2023) Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies. Essays in Biochemistry.
Crossref
Crossref
Zahra Mokhtari, Marzieh Rezaei, Mohammad Hossein Sanei, Amirreza Dehghanian, Zahra Faghih, Zahra Heidari & Shirin Tavana. (2023) Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival. Frontiers in Oncology 13.
Crossref
Crossref
Zhangyan Guo, Rui Zhang, An-Gang Yang & Guoxu Zheng. (2023) Diversity of immune checkpoints in cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Crossref
Jian Tan, Piao Shen, Xingping Yang, Weijie Cai & Hongying Liao. (2023) Characterization of TIM-3 Expression and Its Correlation with TNF-α and IFN-γ in Patients with Surgically Resected Lung Adenocarcinoma. Disease Markers 2023, pages 1-9.
Crossref
Crossref
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil & Maryam Abbaspour. (2022) Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Communications 43:2, pages 177-213.
Crossref
Crossref
Xuewen Deng & Hiroshi Terunuma. (2022) Harnessing NK Cells to Control Metastasis. Vaccines 10:12, pages 2018.
Crossref
Crossref
Enrico Munari, Linda Quatrini, Cecilia Ciancaglini, Albino Eccher, Giuseppe Bogina, Lorenzo Moretta & Francesca Romana Mariotti. (2022) Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. Seminars in Immunology 61-64, pages 101660.
Crossref
Crossref
Sasitorn Yenyuwadee, Konstantinos Aliazis, Qi Wang, Anthos Christofides, Rushil Shah, Nikolaos Patsoukis & Vassiliki A. Boussiotis. (2022) Immune cellular components and signaling pathways in the tumor microenvironment. Seminars in Cancer Biology 86, pages 187-201.
Crossref
Crossref
Melania Grottoli, Paolo Carrega, Lodovica Zullo, Chiara Dellepiane, Giovanni Rossi, Francesca Parisi, Giulia Barletta, Linda Zinoli, Simona Coco, Angela Alama, Silvia Marconi, Monica Parodi, Paola Orecchia, Sara Bassi, Massimo Vitale, Maria Cristina Mingari, Ulrich Pfeffer, Carlo Genova & Gabriella Pietra. (2022) Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. Cancers 14:20, pages 5046.
Crossref
Crossref
Monireh Mohsenzadegan, Mohammad Reza Nowroozi, Amirreza Fotovvat, Parizad Bavandpour Baghshahi, Saied Bokaie, Seyed Hassan Inanloo & Laleh Sharifi. (2022) The prospect of targeting T cell immunoglobulin and mucin‐domain containing‐3 in renal cell carcinoma immunotherapy. Scandinavian Journal of Immunology 96:3.
Crossref
Crossref
Anna Helmin-Basa, Lidia Gackowska, Sara Balcerowska, Marcelina Ornawka, Natalia Naruszewicz & Małgorzata Wiese-Szadkowska. (2022) The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. Physical Sciences Reviews 7:8, pages 833-866.
Crossref
Crossref
Jingyi Tang, Qi Zhu, Zhaoyang Li, Jiahui Yang & Yu Lai. (2022) Natural Killer Cell-targeted Immunotherapy for Cancer. Current Stem Cell Research & Therapy 17:6, pages 513-526.
Crossref
Crossref
Xin Chen, Lei Jiang & Xuesong Liu. (2022) Natural killer cells: the next wave in cancer immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Hajar Alemohammad, Basira Najafzadeh, Zahra Asadzadeh, Amir Baghbanzadeh, Farid Ghorbaninezhad, Arezoo Najafzadeh, Hossein Safarpour, Renato Bernardini, Oronzo Brunetti, Margherita Sonnessa, Rossella Fasano, Nicola Silvestris & Behzad Baradaran. (2022) The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine & Pharmacotherapy 146, pages 112516.
Crossref
Crossref
Cordelia Dunai, Erik Ames, Maria C. Ochoa, Myriam Fernandez-Sendin, Ignacio Melero, Federico Simonetta, Jeanette Baker & Maite Alvarez. 2022. Adoptive Cell Transfer. Adoptive Cell Transfer
65
122
.
Nicolas Jacquelot, Maryam Ghaedi, Kathrin Warner, Douglas C. Chung, Sarah Q. Crome & Pamela S. Ohashi. (2021) Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. Cancers 13:23, pages 5967.
Crossref
Crossref
Irina Buckle & Camille Guillerey. (2021) Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer. Cancers 13:17, pages 4263.
Crossref
Crossref
Simona Sivori, Daniela Pende, Linda Quatrini, Gabriella Pietra, Mariella Della Chiesa, Paola Vacca, Nicola Tumino, Francesca Moretta, Maria Cristina Mingari, Franco Locatelli & Lorenzo Moretta. (2021) NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine 80, pages 100870.
Crossref
Crossref
Benjamin Shibru, Katharina Fey, Stephan Fricke, André-René Blaudszun, Friederike Fürst, Max Weise, Sabine Seiffert, Maria Katharina Weyh, Ulrike Köhl, Ulrich Sack & Andreas Boldt. (2021) Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry. Frontiers in Immunology 12.
Crossref
Crossref
Elena Shklovskaya & Helen Rizos. (2021) MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. International Journal of Molecular Sciences 22:13, pages 6741.
Crossref
Crossref
Raynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise & Daniel Olive. (2021) Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. Journal of Leukocyte Biology 109:6, pages 1071-1088.
Crossref
Crossref
Ross King, Conall Hayes, Claire L Donohoe, Margaret R Dunne, Maria Davern & Noel E Donlon. (2021) Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers. World Journal of Gastrointestinal Oncology 13:5, pages 312-331.
Crossref
Crossref
Nayoung Kim, Dong-Hee Lee, Woo Seon Choi, Eunbi Yi, HyoJeong Kim, Jung Min Kim, Hyung-Seung Jin & Hun Sik Kim. (2021) Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. BMB Reports 54:1, pages 44-58.
Crossref
Crossref
Matteo Gallazzi, Denisa Baci, Lorenzo Mortara, Annalisa Bosi, Giuseppe Buono, Angelo Naselli, Andrea Guarneri, Federico Dehò, Paolo Capogrosso, Adriana Albini, Douglas M. Noonan & Antonino Bruno. (2021) Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors. Frontiers in Immunology 11.
Crossref
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, A.P. González-Rodríguez & Segundo González. 2021. Successes and Challenges of NK Immunotherapy. Successes and Challenges of NK Immunotherapy
267
304
.
Silvia Pesce, Sara Trabanelli, Clara Di Vito, Marco Greppi, Valentina Obino, Fabio Guolo, Paola Minetto, Matteo Bozzo, Michela Calvi, Elisa Zaghi, Simona Candiani, Roberto Massimo Lemoli, Camilla Jandus, Domenico Mavilio & Emanuela Marcenaro. (2020) Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. Cancers 12:12, pages 3504.
Crossref
Crossref
Helmi Alfarra, Jackson Weir, Stacy Grieve & Tony Reiman. (2020) Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Frontiers in Immunology 11.
Crossref
Crossref
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, Yu Tian, Chaoliu Dai, Crystal Widarma, Rui Song & Feng Xu. (2020) Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Xueke Fan, Jiangtao Jin, Lichen Yan, Lei Liu, Qin Li & Youqing Xu. (2020) The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer. Clinical Immunology 219, pages 108551.
Crossref
Crossref
Claudia Cantoni, Hannah Wurzer, Clément Thomas & Massimo Vitale. (2020) Escape of tumor cells from the NK cell cytotoxic activity. Journal of Leukocyte Biology 108:4, pages 1339-1360.
Crossref
Crossref
Tram N. Dao, Sagar Utturkar, Nadia Atallah Lanman & Sandro Matosevic. (2020) TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation. Cancers 12:9, pages 2417.
Crossref
Crossref
Sachin Kumar Singh Chauhan, Ulrike Koehl & Stephan Kloess. (2020) Harnessing NK Cell Checkpoint-Modulating Immunotherapies. Cancers 12:7, pages 1807.
Crossref
Crossref
Cai Zhang & Yuxia Liu. (2020) Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. Frontiers in Immunology 11.
Crossref
Crossref
Laura Damele, Selene Ottonello, Maria Cristina Mingari, Gabriella Pietra & Chiara Vitale. (2020) Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?. Cancers 12:4, pages 774.
Crossref
Crossref
Muhammad Khan, Sumbal Arooj & Hua Wang. (2020) NK Cell-Based Immune Checkpoint Inhibition. Frontiers in Immunology 11.
Crossref
Crossref
Jilin Wang, Teddy Yang & Jie Xu. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
619
649
.
Paola Minetto, Fabio Guolo, Silvia Pesce, Marco Greppi, Valentina Obino, Elisa Ferretti, Simona Sivori, Carlo Genova, Roberto Massimo Lemoli & Emanuela Marcenaro. (2019) Harnessing NK Cells for Cancer Treatment. Frontiers in Immunology 10.
Crossref
Crossref
Yujia Zheng, Yu Li, Jingyao Lian, Huiyun Yang, Feng Li, Song Zhao, Yu Qi, Yi Zhang & Lan Huang. (2019) TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. Journal of Translational Medicine 17:1.
Crossref
Crossref
Haoyu Sun & Cheng Sun. (2019) The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. Frontiers in Immunology 10.
Crossref
Crossref
Jonathan J. Hodgins, Sarwat T. Khan, Maria M. Park, Rebecca C. Auer & Michele Ardolino. (2019) Killers 2.0: NK cell therapies at the forefront of cancer control. Journal of Clinical Investigation 129:9, pages 3499-3510.
Crossref
Crossref
Cinzia Solinas, Pushpamali De Silva, Dominique Bron, Karen Willard-Gallo & Dario Sangiolo. (2019) Significance of TIM3 expression in cancer: From biology to the clinic. Seminars in Oncology 46:4-5, pages 372-379.
Crossref
Crossref
Ziqing Chen, Ying Yang, Lisa L. Liu & Andreas Lundqvist. (2019) Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. Cancers 11:7, pages 1040.
Crossref
Crossref
Nayoung Kim, Hyeon Ho Lee, Hyo-Jung Lee, Woo Seon Choi, Jinju Lee & Hun Sik Kim. (2019) Natural killer cells as a promising therapeutic target for cancer immunotherapy. Archives of Pharmacal Research 42:7, pages 591-606.
Crossref
Crossref
Clara Di Vito, Joanna Mikulak, Elisa Zaghi, Silvia Pesce, Emanuela Marcenaro & Domenico Mavilio. (2019) NK cells to cure cancer. Seminars in Immunology 41, pages 101272.
Crossref
Crossref
Seila Lorenzo-Herrero, Alejandro López-Soto, Christian Sordo-Bahamonde, Ana Gonzalez-Rodriguez, Massimo Vitale & Segundo Gonzalez. (2018) NK Cell-Based Immunotherapy in Cancer Metastasis. Cancers 11:1, pages 29.
Crossref
Crossref
Fernando Concha-Benavente, Benjamin Kansy, Jessica Moskovitz, Jennifer Moy, Uma Chandran & Robert L. Ferris. (2018) PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients. Cancer Immunology Research 6:12, pages 1548-1560.
Crossref
Crossref
Nayoung Kim & Hun Sik Kim. (2018) Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Frontiers in Immunology 9.
Crossref
Crossref
Jianwei Gao, Xiangyu Qiu, Xinying Li, Hang Fan, Fang Zhang, Tangfeng Lv & Yong Song. (2018) Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. Biochemical and Biophysical Research Communications 498:3, pages 409-415.
Crossref
Crossref
Hyung-Joon Kwon, Nayoung Kim & Hun Sik Kim. (2017) Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Experimental & Molecular Medicine 49:3, pages e311-e311.
Crossref
Crossref
Madhumita Das, Chen Zhu & Vijay K. Kuchroo. (2017) Tim-3 and its role in regulating anti-tumor immunity. Immunological Reviews 276:1, pages 97-111.
Crossref
Crossref
Shu Su & Baorui Liu. 2017. Personalized Management of Gastric Cancer. Personalized Management of Gastric Cancer
115
130
.
Elisabetta Cariani & Gabriele Missale. 2017. Immunotherapy of Hepatocellular Carcinoma. Immunotherapy of Hepatocellular Carcinoma
19
38
.
Camille Guillerey, Nicholas D Huntington & Mark J Smyth. (2016) Targeting natural killer cells in cancer immunotherapy. Nature Immunology 17:9, pages 1025-1036.
Crossref
Crossref
Peng Du, Ruihua Xiong, Xiaodong Li & Jingting Jiang. (2016) Immune Regulation and Antitumor Effect of TIM-1. Journal of Immunology Research 2016, pages 1-6.
Crossref
Crossref